WSWan Su

Wan Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wan Su has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Zhongqi Wang

    Department of Medical Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, China

    2 shared publications
  • Chengcheng Zhang

    Department of Medical Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China

    1 shared publication
  • Di Pan

    Department of Traditional Chinese Medicine, Shanghai General Hospital, Shanghai, China

    1 shared publication
  • Guoying Wang

    Department of Critical Care Medicine, The Second People's Hospital of Dongying, Dongying, Shandong, China

    1 shared publication
  • Hegen Li

    Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • HuiRu Guo

    Department of Oncology, Longhua Hospital, Shanghai University of TCM, 725 Wanping road, Shanghai 200032, China

    1 shared publication

Latest Publications

  • Open Access

    Deciphering tryptophan metabolism in colorectal cancer through multi-omics analysis

    by Chengcheng Zhang, Zhijing Rao, Xiangyang Zhan, Jingru Qin, Lu Yang, Qianqian Yin, Junqing Ji, Xiaoxue Zhao, Yiyi Liu, Zhanhui Lu, et al.


  • Open Access

    Ursolic acid suppresses triple-negative breast cancer progression through mediating FABP4/PPARG pathway

    by Ying Deng, Junyi Wu, Di Pan, Wan Su, Songpo Wang

    Background: Triple-negative breast cancer (TNBC) remains the deadliest subtype of breast cancer owing to high metastatic potential and poor prognosis. Herein, we examined the antitumor effects of ursolic acid (UA), a pentacyclic triterpene compound, against TNBC and the underlying mechanisms. Methods: TNBC cells were exposed to a graded concentration of UA, and cell proliferation and migration were examined through CCK-8 and wound healing assays. Transcriptome data of 116 TNBC and 290 normal tissues were acquired for determining differentially expressed genes. Using the PubChem and the SwissTargetPrediction, potential UA targets were inferred. 10 pairs of human TNBC and normal tissues were gathered for examining the expression of UA targets FABP4 and PPARG. The influence of FABP4/PPARG knockdown and overexpression on the therapeutic effects of UA was then observed. Results: UA treatment hampered proliferation and migration of TNBC cells in a concentration-based fashion. FABP4 and PPARG were determined as targets of UA. Their expression levels were gradually elevated as the increase of UA concentration. Clinically, TNBC tumor tissues displayed notable down-regulation of FABP4 and PPARG in comparison with normal tissues. UA treatment increased PPARG expression and promoted its activation, which could be effectively attenuated by FABP4 knockdown. In addition, the efficacy of UA on suppressing TNBC cell growth and migration was notably reversed and enhanced by FABP4/PPARG knockdown and overexpression, respectively. Conclusions: This study suggests that UA treatment increases PPARG expression through modulating FABP4, thus preventing TNBC progression, expanding the clinical application of UA and providing a theoretical basis for its usage in TNBC treatment.


  • Open Access

    Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients

    by Ling Xu, HeGen Li, ZhenYe Xu, ZhongQi Wang, LingShuang Liu, JianHui Tian, JianLi Sun, Lei Zhou, YiLin Yao, LiJing Jiao, et al.

    Background: Traditional Chinese medicine (TCM) is a widely applied complementary therapy for cancer patients. It can reduce the chemical drugs induced toxic effects to improve the quality of life (QOL). This study applies the highest quality of clinical trial methodology to examine the role of TCM in improving QOL of postoperative non-small-cell lung cancer patients. Methods and design: This study is a multi-center, randomized, placebo-controlled, double-blind trial. Four hundred eighty patients will be recruited into seven different research centers in China. These patients that meet the inclusion criteria will be randomized into either a treatment group or a placebo group. Each group will receive treatments of 3-weekly chemotherapy with TCM or placebo for four cycles. The primary outcome will involve the evaluation of QOL and the secondary outcome assessments will include two-year disease-free survival rate and disease-free survival. Other efficacy assessments are changes of TCM symptoms and toxicity. Side effects and safety profile of the therapy would be evaluated at the same time. The investigators expect that TCM therapy combined with chemotherapy is superior to chemotherapy solely in terms of QOL improvement and disease-free survival extension. "Intention-to-treat" analysis will include all randomized participants. Discussion: The results from the clinical trial will provide evidence for the effectiveness of chemotherapy combined with or without TCM in QOL of postoperative NSCLC patients. Trial registration: Clinical Trials.gov (Identifier: NCT01441752).